Evidence map›Paper›PMID 35600640›Full record

ArticleBioengineering & translational medicine2022

Ferrostatin-1-loaded liposome for treatment of corneal alkali burn via targeting ferroptosis.

Kai Wang, Li Jiang, Yueyang Zhong, Yin Zhang, Qichuan Yin, Su Li, Xiaobo Zhang, Haijie Han, Ke Yao

Open access · goldAbstract read
In one paragraph

Article in Bioengineering & translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 89 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kai WangEye Center, The Second Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China.
Li JiangDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences Hangzhou Normal University Hangzhou China.
Yueyang ZhongEye Center, The Second Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China.
Yin ZhangEye Center, The Second Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China.
Qichuan YinEye Center, The Second Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China.
Su LiEye Center, The Second Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China.
Xiaobo ZhangEye Center, The Second Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China.
Haijie HanEye Center, The Second Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China.
Ke YaoEye Center, The Second Affiliated Hospital, School of Medicine Zhejiang University Hangzhou China.ORCID https://orcid.org/0000-0002-6764-7365
Second Affiliated Hospital of Zhejiang University · CNHangzhou Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alkali burn is a potentially blinding corneal injury. During the progression of alkali burn-induced injury, overwhelmed oxidative stress in the cornea triggers cell damage, including oxidative changes in cellular macromolecules and lipid peroxidation in membranes, leading to impaired corneal transparency, decreased vision, or even blindness. In this study, we identified that ferroptosis, a type of lipid peroxidation-dependent cell death, mediated alkali burn-induced corneal injury. Ferroptosis-targeting therapy protected the cornea from cell damage and neovascularization. However, the specific ferroptosis inhibitor ferrostatin-1 (Fer-1) is hydrophobic and cannot be directly applied in the clinic. Therefore, we developed Fer-1-loaded liposomes (Fer-1-NPs) to improve the bioavailability of Fer-1. Our study demonstrated that Fer-1-NPs exerted remarkable curative effects regarding corneal opacity and neovascularization in vivo. The efficacy was comparable to that of dexamethasone, but without appreciable side effects. The significant suppression of ferroptosis (induced by lipid peroxidation and mitochondria disruption), inflammation, and neovascularization might be the mechanisms underlying the therapeutic effect of Fer-1-NPs. Moreover, the Fer-1-NPs treatment showed no signs of cytotoxicity, hematologic toxicity, or visceral organ damage, which further confirmed the biocompatibility. Overall, Fer-1-NPs provide a new prospect for safe and effective therapy for corneal alkali burn.

Indexed as

corneal alkali burncorneal neovascularizationferroptosisferrostatin‐1liposome

Identifiers

PMID35600640
PMCPMC9115688
OpenAlexW3216124530

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.